SELLAS Life Sciences (SLS) Operating Leases (2019 - 2024)
SELLAS Life Sciences (SLS) has disclosed Operating Leases for 6 consecutive years, with $576000.0 as the latest value for Q3 2024.
- On a quarterly basis, Operating Leases fell 10.56% to $576000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $576000.0, a 10.56% decrease, with the full-year FY2023 number at $460000.0, down 19.72% from a year prior.
- Operating Leases was $576000.0 for Q3 2024 at SELLAS Life Sciences, up from $161000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $1.1 million in Q2 2022 to a low of $123000.0 in Q1 2020.
- A 5-year average of $718947.4 and a median of $749000.0 in 2023 define the central range for Operating Leases.
- Peak YoY movement for Operating Leases: skyrocketed 3114.29% in 2020, then tumbled 78.5% in 2024.
- SELLAS Life Sciences' Operating Leases stood at $825000.0 in 2020, then decreased by 26.06% to $610000.0 in 2021, then fell by 6.07% to $573000.0 in 2022, then decreased by 19.72% to $460000.0 in 2023, then increased by 25.22% to $576000.0 in 2024.
- Per Business Quant, the three most recent readings for SLS's Operating Leases are $576000.0 (Q3 2024), $161000.0 (Q2 2024), and $801000.0 (Q1 2024).